Chemicals
Showing 40651–40800 of 41137 results
-
ZM 241385 is a potent antagonist of A2A adenosine receptors (pIC50 = 9.52 for displacement of 5’-N-ethylcarboxamidoadenosine from rat phaeochromocytoma cell membranes).{32870,27926} It displays little or no activity at other A adenosine receptors. ZM 241385 is active in vivo.{32869,32871} It acts as an inverse agonist at constitutively active mutants of the human A2B adenosine receptor.{32641}
Brand:CaymanSKU:20447 -Available on backorder
ZM 306416 is an inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinase that antagonizes the activity of KDR and Flt VEGF receptors with IC50 values of 100 nM and 2 μM, respectively.{27741} It has also been reported to inhibit EGFR kinase with an IC50 value of < 10 nM, reducing proliferation of EGFR-dependent cancer cells.{27752}
Brand:CaymanSKU:-Out of stock
ZM 306416 is an inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinase that antagonizes the activity of KDR and Flt VEGF receptors with IC50 values of 100 nM and 2 μM, respectively.{27741} It has also been reported to inhibit EGFR kinase with an IC50 value of < 10 nM, reducing proliferation of EGFR-dependent cancer cells.{27752}
Brand:CaymanSKU:-Out of stock
ZM 306416 is an inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinase that antagonizes the activity of KDR and Flt VEGF receptors with IC50 values of 100 nM and 2 μM, respectively.{27741} It has also been reported to inhibit EGFR kinase with an IC50 value of < 10 nM, reducing proliferation of EGFR-dependent cancer cells.{27752}
Brand:CaymanSKU:-Out of stock
ZM 323881 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2; IC50 = 50 = 8 nM) but not basal proliferation or that stimulated by EGF or bFGF (IC50s = >5,000, 1,900, and 1,600 nM, respectively).
Brand:CaymanSKU:21347 -Out of stock
ZM 323881 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2; IC50 = 50 = 8 nM) but not basal proliferation or that stimulated by EGF or bFGF (IC50s = >5,000, 1,900, and 1,600 nM, respectively).
Brand:CaymanSKU:21347 -Out of stock
ZM 323881 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2; IC50 = 50 = 8 nM) but not basal proliferation or that stimulated by EGF or bFGF (IC50s = >5,000, 1,900, and 1,600 nM, respectively).
Brand:CaymanSKU:21347 -Out of stock
ZM 323881 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2; IC50 = 50 = 8 nM) but not basal proliferation or that stimulated by EGF or bFGF (IC50s = >5,000, 1,900, and 1,600 nM, respectively).
Brand:CaymanSKU:21347 -Out of stock
The Ras/Raf-1 signalling pathway is a well-characterized system that links receptor tyrosine kinase (RTK) activation with changes in gene expression and cell behavior. Raf-1 is a serine/threonine protein kinase that phosphorylates and activates MAPK-kinase (MEK) in response to activation by Ras. ZM 336372 is a potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells.{15130} Activation of the Raf-1 signalling pathway using ZM 336372 in human carcinoid tumor cells results in induction of cell cycle inhibitors and suppression of cellular proliferation.{15131}
Brand:CaymanSKU:10010367 - 1 mgAvailable on backorder
The Ras/Raf-1 signalling pathway is a well-characterized system that links receptor tyrosine kinase (RTK) activation with changes in gene expression and cell behavior. Raf-1 is a serine/threonine protein kinase that phosphorylates and activates MAPK-kinase (MEK) in response to activation by Ras. ZM 336372 is a potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells.{15130} Activation of the Raf-1 signalling pathway using ZM 336372 in human carcinoid tumor cells results in induction of cell cycle inhibitors and suppression of cellular proliferation.{15131}
Brand:CaymanSKU:10010367 - 10 mgAvailable on backorder
The Ras/Raf-1 signalling pathway is a well-characterized system that links receptor tyrosine kinase (RTK) activation with changes in gene expression and cell behavior. Raf-1 is a serine/threonine protein kinase that phosphorylates and activates MAPK-kinase (MEK) in response to activation by Ras. ZM 336372 is a potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells.{15130} Activation of the Raf-1 signalling pathway using ZM 336372 in human carcinoid tumor cells results in induction of cell cycle inhibitors and suppression of cellular proliferation.{15131}
Brand:CaymanSKU:10010367 - 25 mgAvailable on backorder
The Ras/Raf-1 signalling pathway is a well-characterized system that links receptor tyrosine kinase (RTK) activation with changes in gene expression and cell behavior. Raf-1 is a serine/threonine protein kinase that phosphorylates and activates MAPK-kinase (MEK) in response to activation by Ras. ZM 336372 is a potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells.{15130} Activation of the Raf-1 signalling pathway using ZM 336372 in human carcinoid tumor cells results in induction of cell cycle inhibitors and suppression of cellular proliferation.{15131}
Brand:CaymanSKU:10010367 - 5 mgAvailable on backorder
Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription (Stat) family.{20362} ZM 39923 is an inhibitor of JAK3 (IC50 = 79 nM) that less potently inhibits epidermal growth factor receptor, JAK1, and cyclin-dependent kinase 4 (IC50s = 2.4, 40, and 10 µM, respectively).{27341} In the absence of the reducing agent dithiothreitol, ZM 39923 also inhibits human tissue transglutaminase 2 (TGM2) and the transglutaminase Factor XIIIa (IC50s= 10 and 25 nM, respectively).{22726} It breaks down in neutral buffer to form ZM 449829, which is also an inhibitor of JAK3, TGM2, and Factor XIIIa.{27341,22726}
Brand:CaymanSKU:-Out of stock
Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription (Stat) family.{20362} ZM 39923 is an inhibitor of JAK3 (IC50 = 79 nM) that less potently inhibits epidermal growth factor receptor, JAK1, and cyclin-dependent kinase 4 (IC50s = 2.4, 40, and 10 µM, respectively).{27341} In the absence of the reducing agent dithiothreitol, ZM 39923 also inhibits human tissue transglutaminase 2 (TGM2) and the transglutaminase Factor XIIIa (IC50s= 10 and 25 nM, respectively).{22726} It breaks down in neutral buffer to form ZM 449829, which is also an inhibitor of JAK3, TGM2, and Factor XIIIa.{27341,22726}
Brand:CaymanSKU:-Out of stock
Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription (Stat) family.{20362} ZM 39923 is an inhibitor of JAK3 (IC50 = 79 nM) that less potently inhibits epidermal growth factor receptor, JAK1, and cyclin-dependent kinase 4 (IC50s = 2.4, 40, and 10 µM, respectively).{27341} In the absence of the reducing agent dithiothreitol, ZM 39923 also inhibits human tissue transglutaminase 2 (TGM2) and the transglutaminase Factor XIIIa (IC50s= 10 and 25 nM, respectively).{22726} It breaks down in neutral buffer to form ZM 449829, which is also an inhibitor of JAK3, TGM2, and Factor XIIIa.{27341,22726}
Brand:CaymanSKU:-Out of stock
The Aurora kinases have important roles in regulating mitosis and cytokinesis, with Aurora B involved in centromere function as part of the Chromosomal Passenger Complex, with survivin, INCENP, and borealin.{18317} ZM 447439 is a selective inhibitor of Aurora B kinase (IC50 = 50 nM), less potently inhibiting Aurora C and A (IC50 = 250 and 1,000 nM, respectively).{18314} It has no effect on several other kinases, including Cdk1, Cdk2, Cdk4, Plk1, CHK1, KDR2, and FAK (IC50 > 10 µM).{18316} ZM 447439 has been used to study the role of Aurora B in molecular events associated with mitosis and cytokinesis.{18316,18315} Moreover, ZM 447439 selectively inhibits proliferating cells rather than non-dividing cells, suggesting its potential in cancer therapy.{18314}
Brand:CaymanSKU:- The Aurora kinases have important roles in regulating mitosis and cytokinesis, with Aurora B involved in centromere function as part of the Chromosomal Passenger Complex, with survivin, INCENP, and borealin.{18317} ZM 447439 is a selective inhibitor of Aurora B kinase (IC50 = 50 nM), less potently inhibiting Aurora C and A (IC50 = 250 and 1,000 nM, respectively).{18314} It has no effect on several other kinases, including Cdk1, Cdk2, Cdk4, Plk1, CHK1, KDR2, and FAK (IC50 > 10 µM).{18316} ZM 447439 has been used to study the role of Aurora B in molecular events associated with mitosis and cytokinesis.{18316,18315} Moreover, ZM 447439 selectively inhibits proliferating cells rather than non-dividing cells, suggesting its potential in cancer therapy.{18314}
Brand:CaymanSKU:- The Aurora kinases have important roles in regulating mitosis and cytokinesis, with Aurora B involved in centromere function as part of the Chromosomal Passenger Complex, with survivin, INCENP, and borealin.{18317} ZM 447439 is a selective inhibitor of Aurora B kinase (IC50 = 50 nM), less potently inhibiting Aurora C and A (IC50 = 250 and 1,000 nM, respectively).{18314} It has no effect on several other kinases, including Cdk1, Cdk2, Cdk4, Plk1, CHK1, KDR2, and FAK (IC50 > 10 µM).{18316} ZM 447439 has been used to study the role of Aurora B in molecular events associated with mitosis and cytokinesis.{18316,18315} Moreover, ZM 447439 selectively inhibits proliferating cells rather than non-dividing cells, suggesting its potential in cancer therapy.{18314}
Brand:CaymanSKU:-
Zofenopril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor zofenoprilat.{52243} Zofenopril is hydrolyzed by cardiac esterases in vivo to form zofenoprilat. It inhibits ACE with an IC50 value of 0.9 nM in heart tissue homogenates and inhibits cardiac ACE activity in isolated perfused rat hearts. It reduces mean arterial blood pressure in two kidney-one clip renal hypertensive (2K-1C) rats and spontaneously hypertensive rats (SHRs) when administered at doses of 2.2, 6.6, and 22 mg/kg.{52244} Unlike the ACE inhibitor ramipril (Item No. 15558), zofenopril does not affect bronchoalveolar lavage fluid (BALF) levels of bradykinin or prostaglandin E2 (PGE2; Item No. 14010) or increase coughing induced by citric acid in guinea pigs.{52245}
Brand:CaymanSKU:29525 - 10 mgAvailable on backorder
Zofenopril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor zofenoprilat.{52243} Zofenopril is hydrolyzed by cardiac esterases in vivo to form zofenoprilat. It inhibits ACE with an IC50 value of 0.9 nM in heart tissue homogenates and inhibits cardiac ACE activity in isolated perfused rat hearts. It reduces mean arterial blood pressure in two kidney-one clip renal hypertensive (2K-1C) rats and spontaneously hypertensive rats (SHRs) when administered at doses of 2.2, 6.6, and 22 mg/kg.{52244} Unlike the ACE inhibitor ramipril (Item No. 15558), zofenopril does not affect bronchoalveolar lavage fluid (BALF) levels of bradykinin or prostaglandin E2 (PGE2; Item No. 14010) or increase coughing induced by citric acid in guinea pigs.{52245}
Brand:CaymanSKU:29525 - 25 mgAvailable on backorder
Zofenopril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor zofenoprilat.{52243} Zofenopril is hydrolyzed by cardiac esterases in vivo to form zofenoprilat. It inhibits ACE with an IC50 value of 0.9 nM in heart tissue homogenates and inhibits cardiac ACE activity in isolated perfused rat hearts. It reduces mean arterial blood pressure in two kidney-one clip renal hypertensive (2K-1C) rats and spontaneously hypertensive rats (SHRs) when administered at doses of 2.2, 6.6, and 22 mg/kg.{52244} Unlike the ACE inhibitor ramipril (Item No. 15558), zofenopril does not affect bronchoalveolar lavage fluid (BALF) levels of bradykinin or prostaglandin E2 (PGE2; Item No. 14010) or increase coughing induced by citric acid in guinea pigs.{52245}
Brand:CaymanSKU:29525 - 5 mgAvailable on backorder
Zolazepam (Item No. 21128) is an analytical reference standard categorized as a pyrazolodiazepinone.{58147} Zolazepam has anxiolytic and anticonvulsant properties. Formulations containing zolazepam in combination with tiletamine have been used as canine and feline anesthetics. This product is intended for research and forensic applications.
Brand:CaymanSKU:21128 -Out of stock
Zolazepam (Item No. 21128) is an analytical reference standard categorized as a pyrazolodiazepinone.{58147} Zolazepam has anxiolytic and anticonvulsant properties. Formulations containing zolazepam in combination with tiletamine have been used as canine and feline anesthetics. This product is intended for research and forensic applications.
Brand:CaymanSKU:21128 -Out of stock
Zoledronic acid is a third-generation heterocyclic nitrogen-containing bisphosphonate that inhibits the prenylation of GTPases critical to the signaling events related to osteoclast-mediated bone resorption.{24449} It has a high affinity for hydroxyapatite (Ki = 3.47 μM) and binds directly to mineralized bone where it decreases bone resorption by inhibiting osteoclast proliferation and inducing osteoclast apoptosis.{24450,24449} At μM concentrations, zoledronic acid demonstrates antitumor effects in vitro against breast, prostate, and myeloma cancer cells by inducing cytostasis and prevents bone metastases through its inhibitory effects on adhesion molecules, tumor cell invasion, and angiogenesis.{24449} Zoledronic acid has been used in the treatment of osteoporosis, Paget’s disease, metastatic bone disease, multiple myeloma, hypercalcemia of malignancy, and skeletal-related events associated with metastatic castrate-resistant prostate cancer.{24449,24448,24164,24447,24446}
Brand:CaymanSKU:- Zoledronic acid is a third-generation heterocyclic nitrogen-containing bisphosphonate that inhibits the prenylation of GTPases critical to the signaling events related to osteoclast-mediated bone resorption.{24449} It has a high affinity for hydroxyapatite (Ki = 3.47 μM) and binds directly to mineralized bone where it decreases bone resorption by inhibiting osteoclast proliferation and inducing osteoclast apoptosis.{24450,24449} At μM concentrations, zoledronic acid demonstrates antitumor effects in vitro against breast, prostate, and myeloma cancer cells by inducing cytostasis and prevents bone metastases through its inhibitory effects on adhesion molecules, tumor cell invasion, and angiogenesis.{24449} Zoledronic acid has been used in the treatment of osteoporosis, Paget’s disease, metastatic bone disease, multiple myeloma, hypercalcemia of malignancy, and skeletal-related events associated with metastatic castrate-resistant prostate cancer.{24449,24448,24164,24447,24446}
Brand:CaymanSKU:- Zoledronic acid is a third-generation heterocyclic nitrogen-containing bisphosphonate that inhibits the prenylation of GTPases critical to the signaling events related to osteoclast-mediated bone resorption.{24449} It has a high affinity for hydroxyapatite (Ki = 3.47 μM) and binds directly to mineralized bone where it decreases bone resorption by inhibiting osteoclast proliferation and inducing osteoclast apoptosis.{24450,24449} At μM concentrations, zoledronic acid demonstrates antitumor effects in vitro against breast, prostate, and myeloma cancer cells by inducing cytostasis and prevents bone metastases through its inhibitory effects on adhesion molecules, tumor cell invasion, and angiogenesis.{24449} Zoledronic acid has been used in the treatment of osteoporosis, Paget’s disease, metastatic bone disease, multiple myeloma, hypercalcemia of malignancy, and skeletal-related events associated with metastatic castrate-resistant prostate cancer.{24449,24448,24164,24447,24446}
Brand:CaymanSKU:-
Zolmitriptan is a triptan that acts as an agonist of the serotonin (5-HT; Item No. 14332) receptors 5-HT1B and 5-HT1D (Kis = 2.2 and 0.92 nM, respectively).{25800,25801} Through this action, zolmitriptan inhibits cAMP formation in blood vessels, resulting in vessel constriction.{25800,25801} Triptans, including zolmitriptan, are considered first-line therapy for moderate to severe migraine.{25802}
Brand:CaymanSKU:- Zolmitriptan is a triptan that acts as an agonist of the serotonin (5-HT; Item No. 14332) receptors 5-HT1B and 5-HT1D (Kis = 2.2 and 0.92 nM, respectively).{25800,25801} Through this action, zolmitriptan inhibits cAMP formation in blood vessels, resulting in vessel constriction.{25800,25801} Triptans, including zolmitriptan, are considered first-line therapy for moderate to severe migraine.{25802}
Brand:CaymanSKU:- Zolmitriptan is a triptan that acts as an agonist of the serotonin (5-HT; Item No. 14332) receptors 5-HT1B and 5-HT1D (Kis = 2.2 and 0.92 nM, respectively).{25800,25801} Through this action, zolmitriptan inhibits cAMP formation in blood vessels, resulting in vessel constriction.{25800,25801} Triptans, including zolmitriptan, are considered first-line therapy for moderate to severe migraine.{25802}
Brand:CaymanSKU:- Zolmitriptan is a triptan that acts as an agonist of the serotonin (5-HT; Item No. 14332) receptors 5-HT1B and 5-HT1D (Kis = 2.2 and 0.92 nM, respectively).{25800,25801} Through this action, zolmitriptan inhibits cAMP formation in blood vessels, resulting in vessel constriction.{25800,25801} Triptans, including zolmitriptan, are considered first-line therapy for moderate to severe migraine.{25802}
Brand:CaymanSKU:-
The sodium-hydrogen exchanger isoform-1 (NHE-1) is the most predominant isoform of the Na+/H+ exchanger and is expressed in the heart where it contributes to cardiomyocyte pH homeostasis.{22706} It plays an important role in the myocardial response to ischemia-reperfusion. Zoniporide inhibits human NHE-1 with an IC50 value of 14 nM, displaying greater than 150-fold selectivity over other NHE isoforms.{25880} It has been shown to reduce infarct size in a rabbit myocardial ischemia-reperfusion model without adversely affecting hemodynamics or cardiac function.{22706} In isolated heart, zoniporide reduced infarct size with an EC50 value of 0.25 nM.{25880}
Brand:CaymanSKU:- The sodium-hydrogen exchanger isoform-1 (NHE-1) is the most predominant isoform of the Na+/H+ exchanger and is expressed in the heart where it contributes to cardiomyocyte pH homeostasis.{22706} It plays an important role in the myocardial response to ischemia-reperfusion. Zoniporide inhibits human NHE-1 with an IC50 value of 14 nM, displaying greater than 150-fold selectivity over other NHE isoforms.{25880} It has been shown to reduce infarct size in a rabbit myocardial ischemia-reperfusion model without adversely affecting hemodynamics or cardiac function.{22706} In isolated heart, zoniporide reduced infarct size with an EC50 value of 0.25 nM.{25880}
Brand:CaymanSKU:- The sodium-hydrogen exchanger isoform-1 (NHE-1) is the most predominant isoform of the Na+/H+ exchanger and is expressed in the heart where it contributes to cardiomyocyte pH homeostasis.{22706} It plays an important role in the myocardial response to ischemia-reperfusion. Zoniporide inhibits human NHE-1 with an IC50 value of 14 nM, displaying greater than 150-fold selectivity over other NHE isoforms.{25880} It has been shown to reduce infarct size in a rabbit myocardial ischemia-reperfusion model without adversely affecting hemodynamics or cardiac function.{22706} In isolated heart, zoniporide reduced infarct size with an EC50 value of 0.25 nM.{25880}
Brand:CaymanSKU:- The sodium-hydrogen exchanger isoform-1 (NHE-1) is the most predominant isoform of the Na+/H+ exchanger and is expressed in the heart where it contributes to cardiomyocyte pH homeostasis.{22706} It plays an important role in the myocardial response to ischemia-reperfusion. Zoniporide inhibits human NHE-1 with an IC50 value of 14 nM, displaying greater than 150-fold selectivity over other NHE isoforms.{25880} It has been shown to reduce infarct size in a rabbit myocardial ischemia-reperfusion model without adversely affecting hemodynamics or cardiac function.{22706} In isolated heart, zoniporide reduced infarct size with an EC50 value of 0.25 nM.{25880}
Brand:CaymanSKU:-
Zonisamide is a broad-spectrum sulfonamide antiepileptic agent.{41543} It selectively blocks the repeated firing of sodium channels (IC50 = 2 μg/ml) at low concentrations in mouse embryo spinal cord neurons, and it blocks spontaneous channel firing at concentrations above 10 μg/ml.{41545} In rat cerebral cortex neurons, zonisamide (1-1000 μM) dose-dependently blocks T-type calcium channels with a maximum reduction of 60% of the calcium current.{41546} Zonisamide inhibits recombinant H. pylori carbonic anhydrase (CA) and human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.{33180,41544} Zonisamide has anticonvulsant activity in rats, rabbits, dogs, and mice with a potency similar to phenobarbital (Item No. 9001494) and carbamazepine in maximal electroshock seizure (MES) models.{41543} In mice, it has anticonvulsant activity against MES and pentylenetetrazole-induced maximal and minimal seizures with median effective doses of 19.6, 9.3, and >500 mg/kg, respectively. Zonisamide (10-100 mg/kg, p.o.) dose-dependently prevents reduction of dopamine (Item No. 21992), homovanillic acid (HVA), and dihydroxyphenyl acetic acid (DOPAC) levels and the elevation of the dopamine turnover rate induced by MPTP in mouse striatum. Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.
Brand:CaymanSKU:24183 - 1 gAvailable on backorder
Zonisamide is a broad-spectrum sulfonamide antiepileptic agent.{41543} It selectively blocks the repeated firing of sodium channels (IC50 = 2 μg/ml) at low concentrations in mouse embryo spinal cord neurons, and it blocks spontaneous channel firing at concentrations above 10 μg/ml.{41545} In rat cerebral cortex neurons, zonisamide (1-1000 μM) dose-dependently blocks T-type calcium channels with a maximum reduction of 60% of the calcium current.{41546} Zonisamide inhibits recombinant H. pylori carbonic anhydrase (CA) and human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.{33180,41544} Zonisamide has anticonvulsant activity in rats, rabbits, dogs, and mice with a potency similar to phenobarbital (Item No. 9001494) and carbamazepine in maximal electroshock seizure (MES) models.{41543} In mice, it has anticonvulsant activity against MES and pentylenetetrazole-induced maximal and minimal seizures with median effective doses of 19.6, 9.3, and >500 mg/kg, respectively. Zonisamide (10-100 mg/kg, p.o.) dose-dependently prevents reduction of dopamine (Item No. 21992), homovanillic acid (HVA), and dihydroxyphenyl acetic acid (DOPAC) levels and the elevation of the dopamine turnover rate induced by MPTP in mouse striatum. Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.
Brand:CaymanSKU:24183 - 100 mgAvailable on backorder
Zonisamide is a broad-spectrum sulfonamide antiepileptic agent.{41543} It selectively blocks the repeated firing of sodium channels (IC50 = 2 μg/ml) at low concentrations in mouse embryo spinal cord neurons, and it blocks spontaneous channel firing at concentrations above 10 μg/ml.{41545} In rat cerebral cortex neurons, zonisamide (1-1000 μM) dose-dependently blocks T-type calcium channels with a maximum reduction of 60% of the calcium current.{41546} Zonisamide inhibits recombinant H. pylori carbonic anhydrase (CA) and human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.{33180,41544} Zonisamide has anticonvulsant activity in rats, rabbits, dogs, and mice with a potency similar to phenobarbital (Item No. 9001494) and carbamazepine in maximal electroshock seizure (MES) models.{41543} In mice, it has anticonvulsant activity against MES and pentylenetetrazole-induced maximal and minimal seizures with median effective doses of 19.6, 9.3, and >500 mg/kg, respectively. Zonisamide (10-100 mg/kg, p.o.) dose-dependently prevents reduction of dopamine (Item No. 21992), homovanillic acid (HVA), and dihydroxyphenyl acetic acid (DOPAC) levels and the elevation of the dopamine turnover rate induced by MPTP in mouse striatum. Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.
Brand:CaymanSKU:24183 - 250 mgAvailable on backorder
Zonisamide is a broad-spectrum sulfonamide antiepileptic agent.{41543} It selectively blocks the repeated firing of sodium channels (IC50 = 2 μg/ml) at low concentrations in mouse embryo spinal cord neurons, and it blocks spontaneous channel firing at concentrations above 10 μg/ml.{41545} In rat cerebral cortex neurons, zonisamide (1-1000 μM) dose-dependently blocks T-type calcium channels with a maximum reduction of 60% of the calcium current.{41546} Zonisamide inhibits recombinant H. pylori carbonic anhydrase (CA) and human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.{33180,41544} Zonisamide has anticonvulsant activity in rats, rabbits, dogs, and mice with a potency similar to phenobarbital (Item No. 9001494) and carbamazepine in maximal electroshock seizure (MES) models.{41543} In mice, it has anticonvulsant activity against MES and pentylenetetrazole-induced maximal and minimal seizures with median effective doses of 19.6, 9.3, and >500 mg/kg, respectively. Zonisamide (10-100 mg/kg, p.o.) dose-dependently prevents reduction of dopamine (Item No. 21992), homovanillic acid (HVA), and dihydroxyphenyl acetic acid (DOPAC) levels and the elevation of the dopamine turnover rate induced by MPTP in mouse striatum. Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.
Brand:CaymanSKU:24183 - 500 mgAvailable on backorder
Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide (Item No. 24183) by GC- or LC-MS. Zonisamide is an antiepileptic agent.{41543} It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.{41545} In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.{41546} Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.{33180,41544} In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine (Item No. 21992), but not homovanillic acid (HVA; Item No. 27307) or dihydroxyphenyl acetic acid (DOPAC; Item No. 24912), and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson’s disease.{45492} Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.
Brand:CaymanSKU:28807 - 1 mgAvailable on backorder
Zopolrestat is a potent inhibitor of aldose reductase (IC50s = 1.9 and 41 nM for the human placenta and rat lens enzymes, respectively).{48645} It inhibits sorbitol accumulation in human and rat erythrocytes (IC50s = 370 and 220 nM, respectively). Zopolrestat (50 μM) inhibits ethanol-induced aldose reductase activity and lipid accumulation in HepG2 cells.{48646} In vivo, zopolrestat (50 mg/kg) reduces sciatic nerve, retina, and lens accumulation of sorbitol in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).{48645} It also reduces protein excretion and maintains lens transparency and myo-inositol content, markers of cataract development, in rats with STZ-induced diabetes when administered at a dose of 100 mg/kg.{48647} Zopolrestat also inhibits glyoxalase I (GLOI; Ki = 18 μM).{48648}
Brand:CaymanSKU:29185 - 1 mgAvailable on backorder
Zopolrestat is a potent inhibitor of aldose reductase (IC50s = 1.9 and 41 nM for the human placenta and rat lens enzymes, respectively).{48645} It inhibits sorbitol accumulation in human and rat erythrocytes (IC50s = 370 and 220 nM, respectively). Zopolrestat (50 μM) inhibits ethanol-induced aldose reductase activity and lipid accumulation in HepG2 cells.{48646} In vivo, zopolrestat (50 mg/kg) reduces sciatic nerve, retina, and lens accumulation of sorbitol in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).{48645} It also reduces protein excretion and maintains lens transparency and myo-inositol content, markers of cataract development, in rats with STZ-induced diabetes when administered at a dose of 100 mg/kg.{48647} Zopolrestat also inhibits glyoxalase I (GLOI; Ki = 18 μM).{48648}
Brand:CaymanSKU:29185 - 10 mgAvailable on backorder
Zopolrestat is a potent inhibitor of aldose reductase (IC50s = 1.9 and 41 nM for the human placenta and rat lens enzymes, respectively).{48645} It inhibits sorbitol accumulation in human and rat erythrocytes (IC50s = 370 and 220 nM, respectively). Zopolrestat (50 μM) inhibits ethanol-induced aldose reductase activity and lipid accumulation in HepG2 cells.{48646} In vivo, zopolrestat (50 mg/kg) reduces sciatic nerve, retina, and lens accumulation of sorbitol in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).{48645} It also reduces protein excretion and maintains lens transparency and myo-inositol content, markers of cataract development, in rats with STZ-induced diabetes when administered at a dose of 100 mg/kg.{48647} Zopolrestat also inhibits glyoxalase I (GLOI; Ki = 18 μM).{48648}
Brand:CaymanSKU:29185 - 5 mgAvailable on backorder
Zosuquidar is a modulator of P-glycoprotein (P-gp; Ki = 59 nM).{33874} It restores the sensitivity of P-gp-expressing cancer cells to vinblastine (Item No. 11762), doxorubicin (Item No. 15007), etoposide (Item No. 12092), and paclitaxel (Item No. 10461) when used at 0.1 µM.{33874} It less potently inhibits cytochrome P450 (CYP) isoforms CYP3A, CYP2D6, and CYP2C9 (Kis = 3.8, 25, and 12 µM, respectively).{33875} Zosuquidar does not modulate multidrug resistance-associated protein 1 (MRP-1). Zosuquidar significantly enhances the efficacy of chemotherapeutics in mice implanted with P-gp-expressing tumors.{33874} Through its effects on P-gp, zosuquidar enhances the distribution of P-gp substrates through the blood-brain barrier into the brain.{33873,33876}
Brand:CaymanSKU:21533 -Out of stock
Zosuquidar is a modulator of P-glycoprotein (P-gp; Ki = 59 nM).{33874} It restores the sensitivity of P-gp-expressing cancer cells to vinblastine (Item No. 11762), doxorubicin (Item No. 15007), etoposide (Item No. 12092), and paclitaxel (Item No. 10461) when used at 0.1 µM.{33874} It less potently inhibits cytochrome P450 (CYP) isoforms CYP3A, CYP2D6, and CYP2C9 (Kis = 3.8, 25, and 12 µM, respectively).{33875} Zosuquidar does not modulate multidrug resistance-associated protein 1 (MRP-1). Zosuquidar significantly enhances the efficacy of chemotherapeutics in mice implanted with P-gp-expressing tumors.{33874} Through its effects on P-gp, zosuquidar enhances the distribution of P-gp substrates through the blood-brain barrier into the brain.{33873,33876}
Brand:CaymanSKU:21533 -Out of stock
Zosuquidar is a modulator of P-glycoprotein (P-gp; Ki = 59 nM).{33874} It restores the sensitivity of P-gp-expressing cancer cells to vinblastine (Item No. 11762), doxorubicin (Item No. 15007), etoposide (Item No. 12092), and paclitaxel (Item No. 10461) when used at 0.1 µM.{33874} It less potently inhibits cytochrome P450 (CYP) isoforms CYP3A, CYP2D6, and CYP2C9 (Kis = 3.8, 25, and 12 µM, respectively).{33875} Zosuquidar does not modulate multidrug resistance-associated protein 1 (MRP-1). Zosuquidar significantly enhances the efficacy of chemotherapeutics in mice implanted with P-gp-expressing tumors.{33874} Through its effects on P-gp, zosuquidar enhances the distribution of P-gp substrates through the blood-brain barrier into the brain.{33873,33876}
Brand:CaymanSKU:21533 -Out of stock
Zosuquidar is a modulator of P-glycoprotein (P-gp; Ki = 59 nM).{33874} It restores the sensitivity of P-gp-expressing cancer cells to vinblastine (Item No. 11762), doxorubicin (Item No. 15007), etoposide (Item No. 12092), and paclitaxel (Item No. 10461) when used at 0.1 µM.{33874} It less potently inhibits cytochrome P450 (CYP) isoforms CYP3A, CYP2D6, and CYP2C9 (Kis = 3.8, 25, and 12 µM, respectively).{33875} Zosuquidar does not modulate multidrug resistance-associated protein 1 (MRP-1). Zosuquidar significantly enhances the efficacy of chemotherapeutics in mice implanted with P-gp-expressing tumors.{33874} Through its effects on P-gp, zosuquidar enhances the distribution of P-gp substrates through the blood-brain barrier into the brain.{33873,33876}
Brand:CaymanSKU:21533 -Out of stock
Zotarolimus is a macrocyclic lactone immunosuppressant and a derivative of rapamycin (Item No. 13346).{48775,48776} It binds to FKBP prolyl isomerase 1A (FKBP12; IC50 = 2.57 nM) and inhibits proliferation of human peripheral blood mononuclear cells (PBMCs), rat splenocytes, and human coronary artery smooth muscle cells (IC50s = 7, 1,337, and 0.8 nM, respectively).{48776} Zotarolimus has immunosuppressive activity in a one-way mixed lymphocyte reaction using human or rat lymphocytes (IC50s = 1.2 and 1,465 nM, respectively). It also reduces symptom severity in a rat model of experimental autoimmune encephalomyelitis (EAE; ED50 = 1.17 mg/kg per day) and delays cardiac allograft rejection in rats (ED50 = 3.71 mg/kg per day). Zotarolimus inhibits neointimal formation and reduces stenosis in pig coronary arteries when applied at 10 µg/mm to stainless steel balloon expandable stents with phosphorylcholine in a model of restenosis.{48775} Formulations containing zotarolimus have been used in drug-eluting stents in the prevention of restenosis following stent placement.
Brand:CaymanSKU:29246 - 1 mgAvailable on backorder
Zotarolimus is a macrocyclic lactone immunosuppressant and a derivative of rapamycin (Item No. 13346).{48775,48776} It binds to FKBP prolyl isomerase 1A (FKBP12; IC50 = 2.57 nM) and inhibits proliferation of human peripheral blood mononuclear cells (PBMCs), rat splenocytes, and human coronary artery smooth muscle cells (IC50s = 7, 1,337, and 0.8 nM, respectively).{48776} Zotarolimus has immunosuppressive activity in a one-way mixed lymphocyte reaction using human or rat lymphocytes (IC50s = 1.2 and 1,465 nM, respectively). It also reduces symptom severity in a rat model of experimental autoimmune encephalomyelitis (EAE; ED50 = 1.17 mg/kg per day) and delays cardiac allograft rejection in rats (ED50 = 3.71 mg/kg per day). Zotarolimus inhibits neointimal formation and reduces stenosis in pig coronary arteries when applied at 10 µg/mm to stainless steel balloon expandable stents with phosphorylcholine in a model of restenosis.{48775} Formulations containing zotarolimus have been used in drug-eluting stents in the prevention of restenosis following stent placement.
Brand:CaymanSKU:29246 - 10 mgAvailable on backorder
Zotarolimus is a macrocyclic lactone immunosuppressant and a derivative of rapamycin (Item No. 13346).{48775,48776} It binds to FKBP prolyl isomerase 1A (FKBP12; IC50 = 2.57 nM) and inhibits proliferation of human peripheral blood mononuclear cells (PBMCs), rat splenocytes, and human coronary artery smooth muscle cells (IC50s = 7, 1,337, and 0.8 nM, respectively).{48776} Zotarolimus has immunosuppressive activity in a one-way mixed lymphocyte reaction using human or rat lymphocytes (IC50s = 1.2 and 1,465 nM, respectively). It also reduces symptom severity in a rat model of experimental autoimmune encephalomyelitis (EAE; ED50 = 1.17 mg/kg per day) and delays cardiac allograft rejection in rats (ED50 = 3.71 mg/kg per day). Zotarolimus inhibits neointimal formation and reduces stenosis in pig coronary arteries when applied at 10 µg/mm to stainless steel balloon expandable stents with phosphorylcholine in a model of restenosis.{48775} Formulations containing zotarolimus have been used in drug-eluting stents in the prevention of restenosis following stent placement.
Brand:CaymanSKU:29246 - 25 mgAvailable on backorder
Zotarolimus is a macrocyclic lactone immunosuppressant and a derivative of rapamycin (Item No. 13346).{48775,48776} It binds to FKBP prolyl isomerase 1A (FKBP12; IC50 = 2.57 nM) and inhibits proliferation of human peripheral blood mononuclear cells (PBMCs), rat splenocytes, and human coronary artery smooth muscle cells (IC50s = 7, 1,337, and 0.8 nM, respectively).{48776} Zotarolimus has immunosuppressive activity in a one-way mixed lymphocyte reaction using human or rat lymphocytes (IC50s = 1.2 and 1,465 nM, respectively). It also reduces symptom severity in a rat model of experimental autoimmune encephalomyelitis (EAE; ED50 = 1.17 mg/kg per day) and delays cardiac allograft rejection in rats (ED50 = 3.71 mg/kg per day). Zotarolimus inhibits neointimal formation and reduces stenosis in pig coronary arteries when applied at 10 µg/mm to stainless steel balloon expandable stents with phosphorylcholine in a model of restenosis.{48775} Formulations containing zotarolimus have been used in drug-eluting stents in the prevention of restenosis following stent placement.
Brand:CaymanSKU:29246 - 5 mgAvailable on backorder
Zotepine is an atypical antipsychotic.{38700} It is a dopamine D2 and D3 receptor antagonist (Kis = 5.37 and 6.45 nm, respectively) that reverses dopamine inhibition of forskolin-stimulated cAMP production in CHO cells expressing human D2 and D3 receptors. In vivo, zotepine inhibits head twitches induced by 5-hydroxy-L-tryptophan (Item No. 20539), a behavior mediated by the serotonin (5-HT) receptor subtype 5-HT2, in mice (ED50 = 0.13 mg/kg).{38701} It acts as an α2-adrenergic receptor (α2-AR) antagonist, reducing the hind limb flexor reflex stimulated by clonidine (Item No. 15949) in rats. Zotepine blocks gnawing behavior and body turning induced by apomorphine (Item No. 16094) and methamphetamine in rats.{38702} It also induces catalepsy and inhibits apomorphine-induced vomiting in dogs. Formulations containing zotepine have been used in the treatment of schizophrenia and acute mania.
Brand:CaymanSKU:23909 - 10 mgAvailable on backorder
Zotepine is an atypical antipsychotic.{38700} It is a dopamine D2 and D3 receptor antagonist (Kis = 5.37 and 6.45 nm, respectively) that reverses dopamine inhibition of forskolin-stimulated cAMP production in CHO cells expressing human D2 and D3 receptors. In vivo, zotepine inhibits head twitches induced by 5-hydroxy-L-tryptophan (Item No. 20539), a behavior mediated by the serotonin (5-HT) receptor subtype 5-HT2, in mice (ED50 = 0.13 mg/kg).{38701} It acts as an α2-adrenergic receptor (α2-AR) antagonist, reducing the hind limb flexor reflex stimulated by clonidine (Item No. 15949) in rats. Zotepine blocks gnawing behavior and body turning induced by apomorphine (Item No. 16094) and methamphetamine in rats.{38702} It also induces catalepsy and inhibits apomorphine-induced vomiting in dogs. Formulations containing zotepine have been used in the treatment of schizophrenia and acute mania.
Brand:CaymanSKU:23909 - 100 mgAvailable on backorder
Zotepine is an atypical antipsychotic.{38700} It is a dopamine D2 and D3 receptor antagonist (Kis = 5.37 and 6.45 nm, respectively) that reverses dopamine inhibition of forskolin-stimulated cAMP production in CHO cells expressing human D2 and D3 receptors. In vivo, zotepine inhibits head twitches induced by 5-hydroxy-L-tryptophan (Item No. 20539), a behavior mediated by the serotonin (5-HT) receptor subtype 5-HT2, in mice (ED50 = 0.13 mg/kg).{38701} It acts as an α2-adrenergic receptor (α2-AR) antagonist, reducing the hind limb flexor reflex stimulated by clonidine (Item No. 15949) in rats. Zotepine blocks gnawing behavior and body turning induced by apomorphine (Item No. 16094) and methamphetamine in rats.{38702} It also induces catalepsy and inhibits apomorphine-induced vomiting in dogs. Formulations containing zotepine have been used in the treatment of schizophrenia and acute mania.
Brand:CaymanSKU:23909 - 25 mgAvailable on backorder
Zotepine is an atypical antipsychotic.{38700} It is a dopamine D2 and D3 receptor antagonist (Kis = 5.37 and 6.45 nm, respectively) that reverses dopamine inhibition of forskolin-stimulated cAMP production in CHO cells expressing human D2 and D3 receptors. In vivo, zotepine inhibits head twitches induced by 5-hydroxy-L-tryptophan (Item No. 20539), a behavior mediated by the serotonin (5-HT) receptor subtype 5-HT2, in mice (ED50 = 0.13 mg/kg).{38701} It acts as an α2-adrenergic receptor (α2-AR) antagonist, reducing the hind limb flexor reflex stimulated by clonidine (Item No. 15949) in rats. Zotepine blocks gnawing behavior and body turning induced by apomorphine (Item No. 16094) and methamphetamine in rats.{38702} It also induces catalepsy and inhibits apomorphine-induced vomiting in dogs. Formulations containing zotepine have been used in the treatment of schizophrenia and acute mania.
Brand:CaymanSKU:23909 - 50 mgAvailable on backorder
Zoxazolamine is a potent skeletal muscle relaxant that also has uricosuric activity.{28606} It is metabolized by an array of cytochrome P450 (CYP450) isoforms. As a result, recovery time from zoxazolamine-induced paralysis is used as a measure for change in CYP450 expression in mice.{28604,28603} Zoxazolamine also dose-dependently modulates the expression of pigmentation factors in a keratinocyte-melanocyte co-culture system.{28605}
Brand:CaymanSKU:-Available on backorder
Zoxazolamine is a potent skeletal muscle relaxant that also has uricosuric activity.{28606} It is metabolized by an array of cytochrome P450 (CYP450) isoforms. As a result, recovery time from zoxazolamine-induced paralysis is used as a measure for change in CYP450 expression in mice.{28604,28603} Zoxazolamine also dose-dependently modulates the expression of pigmentation factors in a keratinocyte-melanocyte co-culture system.{28605}
Brand:CaymanSKU:-Available on backorder
Zoxazolamine is a potent skeletal muscle relaxant that also has uricosuric activity.{28606} It is metabolized by an array of cytochrome P450 (CYP450) isoforms. As a result, recovery time from zoxazolamine-induced paralysis is used as a measure for change in CYP450 expression in mice.{28604,28603} Zoxazolamine also dose-dependently modulates the expression of pigmentation factors in a keratinocyte-melanocyte co-culture system.{28605}
Brand:CaymanSKU:-Available on backorder
Zoxazolamine is a potent skeletal muscle relaxant that also has uricosuric activity.{28606} It is metabolized by an array of cytochrome P450 (CYP450) isoforms. As a result, recovery time from zoxazolamine-induced paralysis is used as a measure for change in CYP450 expression in mice.{28604,28603} Zoxazolamine also dose-dependently modulates the expression of pigmentation factors in a keratinocyte-melanocyte co-culture system.{28605}
Brand:CaymanSKU:-Available on backorder
ZSTK474 is a triazine derivative that acts as an inhibitor of class I phosphatidylinositol 3-kinase (PI3K) isoforms (IC50s = 17, 53, and 6 nM for p110β, -γ, and -δ, respectively).{29699} It is selective for PI3K, as it has negligible activity against 139 other kinases when tested at 30 µM.{29699} ZSTK474 is orally bioavailable and shows strong antitumor activity against human cancer xenografts in mice.{29699} The efficacy of ZSTK474 against certain cancer cells and tumors can be enhanced by combination therapy.{29698,29697}
Brand:CaymanSKU:-Available on backorder
ZSTK474 is a triazine derivative that acts as an inhibitor of class I phosphatidylinositol 3-kinase (PI3K) isoforms (IC50s = 17, 53, and 6 nM for p110β, -γ, and -δ, respectively).{29699} It is selective for PI3K, as it has negligible activity against 139 other kinases when tested at 30 µM.{29699} ZSTK474 is orally bioavailable and shows strong antitumor activity against human cancer xenografts in mice.{29699} The efficacy of ZSTK474 against certain cancer cells and tumors can be enhanced by combination therapy.{29698,29697}
Brand:CaymanSKU:-Available on backorder
ZSTK474 is a triazine derivative that acts as an inhibitor of class I phosphatidylinositol 3-kinase (PI3K) isoforms (IC50s = 17, 53, and 6 nM for p110β, -γ, and -δ, respectively).{29699} It is selective for PI3K, as it has negligible activity against 139 other kinases when tested at 30 µM.{29699} ZSTK474 is orally bioavailable and shows strong antitumor activity against human cancer xenografts in mice.{29699} The efficacy of ZSTK474 against certain cancer cells and tumors can be enhanced by combination therapy.{29698,29697}
Brand:CaymanSKU:-Available on backorder
ZSTK474 is a triazine derivative that acts as an inhibitor of class I phosphatidylinositol 3-kinase (PI3K) isoforms (IC50s = 17, 53, and 6 nM for p110β, -γ, and -δ, respectively).{29699} It is selective for PI3K, as it has negligible activity against 139 other kinases when tested at 30 µM.{29699} ZSTK474 is orally bioavailable and shows strong antitumor activity against human cancer xenografts in mice.{29699} The efficacy of ZSTK474 against certain cancer cells and tumors can be enhanced by combination therapy.{29698,29697}
Brand:CaymanSKU:-Available on backorder
Zuclopenthixol is a dopamine receptor antagonist (Kis = 9.8 and 1.5 nM for D1 and D2 receptors, respectively).{39773} It also binds to serotonin (5-HT) receptor subtypes 5-HT2 and 5-HT6, α1-adrenergic, and histamine receptors (Kis = 7.6, 3, 33, and 169 nM, respectively) but not α2-adrenergic receptors (Ki = >4,300 nM).{39773,39774} Zuclopenthixol inhibits dopamine-induced accumulation of cAMP in rat striatal homogenates (IC50 = 330 nM; Ki = 16 nM).{39774} It decreases stereotypic behavior induced by methylphenidate in mice (ED50 = 0.8 µmol/kg) and by apomorphine in rats and dogs (ED50s = 6.0 and 1.3 µmol/kg, respectively). Zuclopenthixol (0.7 and 1.4 mg/kg, i.p.) administered prior to testing enhances memory retrieval in rats in an inhibitory avoidance task without affecting locomotor activity.{39775}
Brand:CaymanSKU:24961 - 100 mgAvailable on backorder
Zuclopenthixol is a dopamine receptor antagonist (Kis = 9.8 and 1.5 nM for D1 and D2 receptors, respectively).{39773} It also binds to serotonin (5-HT) receptor subtypes 5-HT2 and 5-HT6, α1-adrenergic, and histamine receptors (Kis = 7.6, 3, 33, and 169 nM, respectively) but not α2-adrenergic receptors (Ki = >4,300 nM).{39773,39774} Zuclopenthixol inhibits dopamine-induced accumulation of cAMP in rat striatal homogenates (IC50 = 330 nM; Ki = 16 nM).{39774} It decreases stereotypic behavior induced by methylphenidate in mice (ED50 = 0.8 µmol/kg) and by apomorphine in rats and dogs (ED50s = 6.0 and 1.3 µmol/kg, respectively). Zuclopenthixol (0.7 and 1.4 mg/kg, i.p.) administered prior to testing enhances memory retrieval in rats in an inhibitory avoidance task without affecting locomotor activity.{39775}
Brand:CaymanSKU:24961 - 250 mgAvailable on backorder
Zuclopenthixol is a dopamine receptor antagonist (Kis = 9.8 and 1.5 nM for D1 and D2 receptors, respectively).{39773} It also binds to serotonin (5-HT) receptor subtypes 5-HT2 and 5-HT6, α1-adrenergic, and histamine receptors (Kis = 7.6, 3, 33, and 169 nM, respectively) but not α2-adrenergic receptors (Ki = >4,300 nM).{39773,39774} Zuclopenthixol inhibits dopamine-induced accumulation of cAMP in rat striatal homogenates (IC50 = 330 nM; Ki = 16 nM).{39774} It decreases stereotypic behavior induced by methylphenidate in mice (ED50 = 0.8 µmol/kg) and by apomorphine in rats and dogs (ED50s = 6.0 and 1.3 µmol/kg, respectively). Zuclopenthixol (0.7 and 1.4 mg/kg, i.p.) administered prior to testing enhances memory retrieval in rats in an inhibitory avoidance task without affecting locomotor activity.{39775}
Brand:CaymanSKU:24961 - 500 mgAvailable on backorder
Zymosan A is a glucan derived from the cell wall of S. cerevisiae that activates toll-like receptor 2 (TLR2) and a C-type lectin, dectin-1, on macrophages, monocytes, and dendritic cells to induce inflammatory signaling.{33697,33696,33699,33701} It is commonly used to stimulate a sterile inflammatory response in mouse models of sepsis, shock, and peritonitis.{33700,9327} In a mouse model of sepsis/shock, a lethal dose of zymosan A (500 mg/kg) in rats induced inflammation and shock leading to death.{33700} Zymosan A can also induce biosynthesis of eicosanoids.{33698}
Brand:CaymanSKU:21175 -Out of stock
Zymosan A is a glucan derived from the cell wall of S. cerevisiae that activates toll-like receptor 2 (TLR2) and a C-type lectin, dectin-1, on macrophages, monocytes, and dendritic cells to induce inflammatory signaling.{33697,33696,33699,33701} It is commonly used to stimulate a sterile inflammatory response in mouse models of sepsis, shock, and peritonitis.{33700,9327} In a mouse model of sepsis/shock, a lethal dose of zymosan A (500 mg/kg) in rats induced inflammation and shock leading to death.{33700} Zymosan A can also induce biosynthesis of eicosanoids.{33698}
Brand:CaymanSKU:21175 -Out of stock
Zymosan A is a glucan derived from the cell wall of S. cerevisiae that activates toll-like receptor 2 (TLR2) and a C-type lectin, dectin-1, on macrophages, monocytes, and dendritic cells to induce inflammatory signaling.{33697,33696,33699,33701} It is commonly used to stimulate a sterile inflammatory response in mouse models of sepsis, shock, and peritonitis.{33700,9327} In a mouse model of sepsis/shock, a lethal dose of zymosan A (500 mg/kg) in rats induced inflammation and shock leading to death.{33700} Zymosan A can also induce biosynthesis of eicosanoids.{33698}
Brand:CaymanSKU:21175 -Out of stock
Zymostenol is a late-stage precursor in the biosynthesis of cholesterol.{48201} It is an agonist of retinoic acid receptor-related orphan receptor γ (RORγ) with an EC50 value of 1 µM in a RORγ coactivator recruitment assay in the presence of ursolic acid (Item No. 10072). It increases the number of myelin basic protein-positive oligodendrocytes generated from oligodendrocyte precursor cells in vitro.{48202} Zymostenol accumulates in cells following administration of microsomal antiestrogen-binding site (AEBS) ligands, such as tamoxifen (Item No. 13258), which are associated with cell differentiation and a protective type of autophagy.{48203,48204} When used alone at a concentration of 20 µM, zymostenol halts the cell cycle at the G0/G1 phase and increases the levels of free sterols, esterified sterols, and triacylglycerols in MCF-7 cells.{48203}
Brand:CaymanSKU:26209 - 10 mgAvailable on backorder
Zymostenol is a late-stage precursor in the biosynthesis of cholesterol.{48201} It is an agonist of retinoic acid receptor-related orphan receptor γ (RORγ) with an EC50 value of 1 µM in a RORγ coactivator recruitment assay in the presence of ursolic acid (Item No. 10072). It increases the number of myelin basic protein-positive oligodendrocytes generated from oligodendrocyte precursor cells in vitro.{48202} Zymostenol accumulates in cells following administration of microsomal antiestrogen-binding site (AEBS) ligands, such as tamoxifen (Item No. 13258), which are associated with cell differentiation and a protective type of autophagy.{48203,48204} When used alone at a concentration of 20 µM, zymostenol halts the cell cycle at the G0/G1 phase and increases the levels of free sterols, esterified sterols, and triacylglycerols in MCF-7 cells.{48203}
Brand:CaymanSKU:26209 - 25 mgAvailable on backorder
Zymostenol is a late-stage precursor in the biosynthesis of cholesterol.{48201} It is an agonist of retinoic acid receptor-related orphan receptor γ (RORγ) with an EC50 value of 1 µM in a RORγ coactivator recruitment assay in the presence of ursolic acid (Item No. 10072). It increases the number of myelin basic protein-positive oligodendrocytes generated from oligodendrocyte precursor cells in vitro.{48202} Zymostenol accumulates in cells following administration of microsomal antiestrogen-binding site (AEBS) ligands, such as tamoxifen (Item No. 13258), which are associated with cell differentiation and a protective type of autophagy.{48203,48204} When used alone at a concentration of 20 µM, zymostenol halts the cell cycle at the G0/G1 phase and increases the levels of free sterols, esterified sterols, and triacylglycerols in MCF-7 cells.{48203}
Brand:CaymanSKU:26209 - 5 mgAvailable on backorder
Zymostenol is a late-stage precursor in the biosynthesis of cholesterol.{48201} It is an agonist of retinoic acid receptor-related orphan receptor γ (RORγ) with an EC50 value of 1 µM in a RORγ coactivator recruitment assay in the presence of ursolic acid (Item No. 10072). It increases the number of myelin basic protein-positive oligodendrocytes generated from oligodendrocyte precursor cells in vitro.{48202} Zymostenol accumulates in cells following administration of microsomal antiestrogen-binding site (AEBS) ligands, such as tamoxifen (Item No. 13258), which are associated with cell differentiation and a protective type of autophagy.{48203,48204} When used alone at a concentration of 20 µM, zymostenol halts the cell cycle at the G0/G1 phase and increases the levels of free sterols, esterified sterols, and triacylglycerols in MCF-7 cells.{48203}
Brand:CaymanSKU:26209 - 50 mgAvailable on backorder
α C16 Galactosylceramide is a glycosphingolipid that contains a galactose moiety attached to a ceramide acylated with palmitic acid (Item No. 10006627).
Brand:CaymanSKU:26009 - 1 mgAvailable on backorder
α C16 Galactosylceramide is a glycosphingolipid that contains a galactose moiety attached to a ceramide acylated with palmitic acid (Item No. 10006627).
Brand:CaymanSKU:26009 - 5 mgAvailable on backorder
Bacteria synthesize the cellular growth factor putrescine through a number of pathways. One pathway involves the decarboxylation of arginine by arginine decarboxylase to produce agmatine, which is then degraded to putrescine. While important for various cellular processes (e.g., cell division, differentiation, environmental stress responses) in all living organisms, including plants, high levels of this polyamine can be toxic.{23742} α-(difluoromethyl)-DL-Arginine (DFMA) is an enzyme-activated, irreversible inhibitor of the arginine decarboxylases of E. coli (Ki = 800 µM), P. aeruginosa, and K. pneumoniae.{26879} At 0.01 mM, it has been shown to prevent the osmotic stress-induced increase in arginine decarboxylase activity and putrescine synthesis in oat leaf cells.{26875,26878} DFMA can also reduce the growth of T. cruzi in mammalian host cells at a minimal concentration of 10 mM and prevent the growth of C. parvum in a T cell receptor alpha-deficient mouse model when combined with various polyamine analogs.{26877,26876}
Brand:CaymanSKU:-Out of stock
Bacteria synthesize the cellular growth factor putrescine through a number of pathways. One pathway involves the decarboxylation of arginine by arginine decarboxylase to produce agmatine, which is then degraded to putrescine. While important for various cellular processes (e.g., cell division, differentiation, environmental stress responses) in all living organisms, including plants, high levels of this polyamine can be toxic.{23742} α-(difluoromethyl)-DL-Arginine (DFMA) is an enzyme-activated, irreversible inhibitor of the arginine decarboxylases of E. coli (Ki = 800 µM), P. aeruginosa, and K. pneumoniae.{26879} At 0.01 mM, it has been shown to prevent the osmotic stress-induced increase in arginine decarboxylase activity and putrescine synthesis in oat leaf cells.{26875,26878} DFMA can also reduce the growth of T. cruzi in mammalian host cells at a minimal concentration of 10 mM and prevent the growth of C. parvum in a T cell receptor alpha-deficient mouse model when combined with various polyamine analogs.{26877,26876}
Brand:CaymanSKU:-Out of stock
Bacteria synthesize the cellular growth factor putrescine through a number of pathways. One pathway involves the decarboxylation of arginine by arginine decarboxylase to produce agmatine, which is then degraded to putrescine. While important for various cellular processes (e.g., cell division, differentiation, environmental stress responses) in all living organisms, including plants, high levels of this polyamine can be toxic.{23742} α-(difluoromethyl)-DL-Arginine (DFMA) is an enzyme-activated, irreversible inhibitor of the arginine decarboxylases of E. coli (Ki = 800 µM), P. aeruginosa, and K. pneumoniae.{26879} At 0.01 mM, it has been shown to prevent the osmotic stress-induced increase in arginine decarboxylase activity and putrescine synthesis in oat leaf cells.{26875,26878} DFMA can also reduce the growth of T. cruzi in mammalian host cells at a minimal concentration of 10 mM and prevent the growth of C. parvum in a T cell receptor alpha-deficient mouse model when combined with various polyamine analogs.{26877,26876}
Brand:CaymanSKU:-Out of stock
Bacteria synthesize the cellular growth factor putrescine through a number of pathways. One pathway involves the decarboxylation of arginine by arginine decarboxylase to produce agmatine, which is then degraded to putrescine. While important for various cellular processes (e.g., cell division, differentiation, environmental stress responses) in all living organisms, including plants, high levels of this polyamine can be toxic.{23742} α-(difluoromethyl)-DL-Arginine (DFMA) is an enzyme-activated, irreversible inhibitor of the arginine decarboxylases of E. coli (Ki = 800 µM), P. aeruginosa, and K. pneumoniae.{26879} At 0.01 mM, it has been shown to prevent the osmotic stress-induced increase in arginine decarboxylase activity and putrescine synthesis in oat leaf cells.{26875,26878} DFMA can also reduce the growth of T. cruzi in mammalian host cells at a minimal concentration of 10 mM and prevent the growth of C. parvum in a T cell receptor alpha-deficient mouse model when combined with various polyamine analogs.{26877,26876}
Brand:CaymanSKU:-Out of stock
α-acetyl Boswellic acid is a pentacyclic triterpene and isomer of β-acetyl-boswellic acid (Item No. 11674) originally isolated from B. serrata.{42584} It inhibits LPS-induced TNF-α mRNA expression in monocytes as well as NF-κB activity in HEK293 cells when used at a concentration of 10 μM.{42584} α-acetyl Boswellic acid also inhibits phosphorylation of IκBα mediated by IκB kinases (IKKs) in monocytes.
Brand:CaymanSKU:11673 - 1 mgAvailable on backorder
α-acetyl Boswellic acid is a pentacyclic triterpene and isomer of β-acetyl-boswellic acid (Item No. 11674) originally isolated from B. serrata.{42584} It inhibits LPS-induced TNF-α mRNA expression in monocytes as well as NF-κB activity in HEK293 cells when used at a concentration of 10 μM.{42584} α-acetyl Boswellic acid also inhibits phosphorylation of IκBα mediated by IκB kinases (IKKs) in monocytes.
Brand:CaymanSKU:11673 - 10 mgAvailable on backorder
α-acetyl Boswellic acid is a pentacyclic triterpene and isomer of β-acetyl-boswellic acid (Item No. 11674) originally isolated from B. serrata.{42584} It inhibits LPS-induced TNF-α mRNA expression in monocytes as well as NF-κB activity in HEK293 cells when used at a concentration of 10 μM.{42584} α-acetyl Boswellic acid also inhibits phosphorylation of IκBα mediated by IκB kinases (IKKs) in monocytes.
Brand:CaymanSKU:11673 - 5 mgAvailable on backorder